1216796-18-7
1216796-18-7
Chemical Structure
Amiloride-15N3 hydrochloride
Synonym(s): MK-870-15N3 hydrochloride
- CAS No.: 1216796-18-7
- Formula:C6H9Cl2N415N3O
- Molecular Weight:269.07
IUPAC Name: 3,5-diamino-N-(carbamimidoyl-15N2)-6-chloropyrazine-2-carboxamide-N-15N hydrochloride
InChIKey: ACHKKGDWZVCSNH-FORMCRCZSA-N
SMILES: [15NH]=C([15NH2])[15NH]C(C1=NC(Cl)=C(N)N=C1N)=O.Cl
Biological Activity: Amiloride-15N3 (hydrochloride) is the 15N labeled Amiloride hydrochloride[1]. Amiloride hydrochloride (MK-870 hydrochloride) is an inhibitor of both epithelial sodium channel (ENaC[2]) and urokinase-type plasminogen activator receptor (uTPA[3]). Amiloride hydrochloride is a blocker of polycystin-2 (PC2;TRPP2[4]) channel.
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Amiloride-15N3 hydrochloride | Amiloride-15N3 (hydrochloride) is the 15N labeled Amiloride hydrochloride. Amiloride hydrochloride (MK-870 hydrochloride) is an inhibitor of both epithelial sodium channel (ENaC) and urokinase-type plasminogen activator receptor (uTPA). Amiloride hydrochloride is a blocker of polycystin-2 (PC2;TRPP2) channel. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Amiloride hydrochloride (Standard) | 99.59% | Amiloride (hydrochloride) (Standard) is the analytical standard of Amiloride (hydrochloride). This product is intended for research and analytical applications. Amiloride hydrochloride (MK-870 hydrochloride) is an inhibitor of both epithelial sodium channel (ENaC) and urokinase-type plasminogen activator receptor (uTPA). Amiloride hydrochloride is a blocker of polycystin-2 (PC2; TRPP2) channel. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Amiloride hydrochloride | 99.84% | Amiloride hydrochloride (MK-870 hydrochloride) is an inhibitor of both epithelial sodium channel (ENaC) and urokinase-type plasminogen activator receptor (uTPA). Amiloride hydrochloride is a blocker of polycystin-2 (PC2; TRPP2) channel. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
- [2]. Ji, H.L., et al. delta ENaC: a novel divergent amiloride-inhibitable sodium channel. Am J Physiol Lung Cell Mol Physiol, 2012. 303(12): p. L1013-26. [Content Brief]
- [3]. Teiwes J, et al. Epithelial sodium channel inhibition in cardiovascular disease. A potential role for amiloride. Am J Hypertens. 2007 Jan20(1):109-17. [Content Brief]
- [4]. Giamarchi A, et al. A polycystin-2 (TRPP2) dimerization domain essential for the function of heteromeric polycystin complexes. EMBO J. 2010 Apr 729(7):1176-91. [Content Brief]
